Literature DB >> 16628460

Optic pathway glioma: outcome and prognostic factors in a surgical series.

Yong Ahn1, Byung-Kyu Cho, Seung-Ki Kim, You-Nam Chung, Chang Sub Lee, Il Han Kim, Sei Won Yang, Hee-Soo Kim, Hyun Jib Kim, Hee-Won Jung, Kyu-Chang Wang.   

Abstract

OBJECTS: The goals of this study were to evaluate the surgical outcomes of optic pathway glioma (OPG) and to analyze the prognostic factors related to the progression-free survival.
MATERIALS AND METHODS: A retrospective review was conducted on 33 patients who underwent surgery for OPG; these included 15 male and 18 female patients with a mean age of 8.3 years. The mean duration of follow-up was 52 months. RESULTS AND
CONCLUSIONS: The preservation rate of ipsilateral vision was 25%, while that of contralateral vision was 83% (P<0.001). There was no remarkable endocrine improvement after surgery. The overall and progression-free survival rates at 5 years were 93.6 and 52.4%, respectively. In our study, the predictors for tumor progression were children younger than 5 years of age (p=0.023) and of female gender (p=0.022). Because of the variable course of OPG, treatment policy should be optimized individually according to patient's status.

Entities:  

Mesh:

Year:  2006        PMID: 16628460     DOI: 10.1007/s00381-006-0086-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  20 in total

1.  Optic pathway hypothalamic gliomas in children under three years of age: the role of chemotherapy.

Authors:  M M Silva; S Goldman; G Keating; M A Marymont; J Kalapurakal; T Tomita
Journal:  Pediatr Neurosurg       Date:  2000-09       Impact factor: 1.162

2.  Spontaneous visual improvement in chiasmal gliomas.

Authors:  G T Liu; S Lessell
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

3.  Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma.

Authors:  P F Collet-Solberg; H Sernyak; M Satin-Smith; L L Katz; L Sutton; P Molloy; T Moshang
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

4.  Diencephalic syndrome of emaciation (Russell's syndrome). Long-term survival.

Authors:  S Namba; A Nishimoto; Y Yagyu
Journal:  Surg Neurol       Date:  1985-06

5.  Hypothalamic glioma.

Authors:  G R Gillett; L Symon
Journal:  Surg Neurol       Date:  1987-10

6.  Spontaneous regression of optic glioma in a patient with neurofibromatosis.

Authors:  A E Brzowski; C Bazan; J V Mumma; S G Ryan
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

Review 7.  An integrated approach to the treatment of chiasmatic-hypothalamic gliomas.

Authors:  M Garvey; R J Packer
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

8.  Surgery of giant gliomas of chiasma and IIIrd ventricle.

Authors:  A Konovalov; S Gorelyshev; N Serova
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

9.  Potential prognostic factors of relapse-free survival in childhood optic pathway glioma: a multivariate analysis.

Authors:  M Y Chan; A P Foong; D M Heisey; W Harkness; R Hayward; A Michalski
Journal:  Pediatr Neurosurg       Date:  1998-07       Impact factor: 1.162

10.  Controversy in the management of optic nerve glioma.

Authors:  L Weiss; R H Sagerman; G A King; C T Chung; R L Dubowy
Journal:  Cancer       Date:  1987-03-01       Impact factor: 6.860

View more
  19 in total

1.  Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions?

Authors:  Kristian Aquilina; David J Daniels; Helen Spoudeas; Kim Phipps; Hoong-Wei Gan; Frederick A Boop
Journal:  Childs Nerv Syst       Date:  2015-08-16       Impact factor: 1.475

Review 2.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

3.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.

Authors:  Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Grant T Liu
Journal:  Neuro Oncol       Date:  2012-04-03       Impact factor: 12.300

4.  Infarction following chiasmatic low grade glioma resection.

Authors:  Markus Hupp; Fabian Falkenstein; Brigitte Bison; Cora Mirow; Jürgen Krauss; Astrid Gnekow; Laszlo Solymosi; Monika Warmuth-Metz
Journal:  Childs Nerv Syst       Date:  2011-10-11       Impact factor: 1.475

5.  Prechiasmatic transection of the optic nerve in optic nerve glioma: technical description and surgical outcome.

Authors:  Hamid Borghei-Razavi; Shunsuke Shibao; Uta Schick
Journal:  Neurosurg Rev       Date:  2016-05-26       Impact factor: 3.042

6.  The role of diffusion tensor tractography in the surgical treatment of pediatric optic chiasmatic gliomas.

Authors:  Ming Ge; ShaoWu Li; Liang Wang; ChunDe Li; Junting Zhang
Journal:  J Neurooncol       Date:  2015-01-24       Impact factor: 4.130

7.  Optic nerve glioma: A great mimicker.

Authors:  Poonam Bhaker; Ruchita Tyagi; Divyesh Mahajan; Sandeep Mohindra; Rakesh K Vasishta
Journal:  Surg Neurol Int       Date:  2014-01-23

8.  Prognostic role for diffusion-weighted imaging of pediatric optic pathway glioma.

Authors:  K W Yeom; R M Lober; J B Andre; P G Fisher; P D Barnes; M S B Edwards; S Partap
Journal:  J Neurooncol       Date:  2013-05-15       Impact factor: 4.130

Review 9.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03

10.  Endoscopic transnasal resection of optic pathway pilocytic astrocytoma.

Authors:  Sarah Bin Abdulqader; Ziyad Al-Ajlan; Abdulrahman Albakr; Wisam Issawi; Mohammed Al-Bar; Pablo F Recinos; Saad Alsaleh; Abdulrazag Ajlan
Journal:  Childs Nerv Syst       Date:  2018-10-18       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.